SecBot SecBot
EFFECT ·Filed Apr 1, 2026

VIVS

VivoSim Labs, INC.
NEUTRAL
Impact 5/10
Horizondays Processed6mo ago SEC9999999995-26-001032
IPO/offering going effective
Actionable Insight • Neutral

Traders should monitor for pricing and closing of the Initial Tranche, which could occur imminently. The conditional Second Tranche creates a potential future catalyst if volume and price conditions are met. The complex warrant structure with cashless exercise mechanics could lead to volatility upon exercise.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
VIVS ▼ -34.57% at T+60d
NEUTRAL call -34.57% · α vs SPY -47.95% · entry $1.62 → $1.06
Entry = T+0 close
Apr 1, 2026
via day close
T+1d
+4.32%
call +4.32% · α +4.24%
$1.69
settled 7mo ago
T+5d
-5.56%
call -5.56% · α -9.32%
$1.53
settled 7mo ago
T+20d
-11.11%
call -11.11% · α -20.83%
$1.44
settled 6mo ago
T+60d
-34.57%
call -34.57% · α -47.95%
$1.06
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

VivoSim Labs' IPO has become effective, allowing the company to begin selling up to $4 million in common stock, pre-funded warrants, and accompanying common warrants in a best-efforts offering. The offering is structured in two tranches, with the second tranche contingent on stock price and trading volume conditions being met 30 days after the initial closing.

Key Facts

  • IPO registration (Form S-1) has become effective as of March 31, 2026
  • Offering size: up to $4 million, split into $3 million Initial Tranche and $1 million Second Tranche
  • Securities offered: up to 2,366,862 shares of common stock (or pre-funded warrants), 3,550,293 common warrants, and 118,343 placement agent warrants
  • Second Tranche is conditional on stock price stability and minimum average daily trading volume of $100,000 over 10 days
  • Common warrants include price protection and a cashless exercise feature using a Black-Scholes valuation model

Financial Impact

Up to $4 million in gross proceeds if both tranches are fully sold; potential for significant dilution due to warrant overhang (up to 11.3 million additional shares possible upon exercise)

dilutionequitymarket_cap

Risk Factors

  • High dilution risk from warrants exercisable for up to 11.3 million additional shares
  • Second Tranche may not close if volume or price conditions are not satisfied
  • Best-efforts offering may result in less than full capital raise

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001032
Document: 9999999995-26-001032-index.html9999999995-26-001032
Document: 9999999995-26-001032.txt9999999995-26-001032
9 reports for VIVS
Performance horizon
100% Hit rate @ T+5 4 of 4 directional calls Went positive at some point 4 of 4 best @ T+60▲ +69.95%Jul 17, 2026
Filters
Rows
Reports for VIVS — sortable, filterable
TypeNow
Oct 16, 2026
10d ago
8-K
BEARISH ★ 5/10
$0.1575 $0.1520▲ +3.49%▲ +3.35%$0.1520 (+3.49%)
Oct 6, 2026
20d ago
8-K
NEUTRAL ★ 4/10
$0.1915 $0.1609▼ −15.98%▼ −15.00%$0.1520 (−20.63%)
Sep 16, 2026
5w ago
Press Release
NEUTRAL ★ 5/10
$0.2621 $0.2291▼ −12.59%▼ −15.15%$0.1520 (−42.01%)
Aug 11, 2026
10w ago
EFFECT
BEARISH ★ 7/10
$0.3526 $0.2786▲ +20.99%▲ +20.58%$0.1520 (+56.89%)
Aug 6, 2026
11w ago
8-K
MIXED ★ 6/10
$0.3299 $0.3281▼ −0.55%▼ −1.76%$0.1520 (−53.93%)
Jul 17, 2026
14w ago
8-K
BEARISH ★ 7/10
$0.5790 $0.4500▲ +22.28%▲ +21.59%$0.1520 (+73.75%)
Apr 3, 2026
29w ago
8-K
NEUTRAL ★ 5/10
$1.71 $1.44▼ −15.79%▼ −19.92%$0.1520 (−91.11%)
Apr 1, 2026
29w ago
Press Release
BEARISH ★ 6/10
$1.62 $1.53▲ +5.56%▲ +9.32%$0.1520 (+90.62%)
Apr 1, 2026
29w ago
EFFECT
NEUTRAL ★ 5/10
$1.62 $1.53▼ −5.56%▼ −9.32%$0.1520 (−90.62%)
Showing 9 of 9

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 1, 2026